Daily tape read: what moved, why it moved, and what the positioning tells you. Feb 18, 2026 session.
Cleanest "science actually moved the stock" print in the last 24h. Second Phase 3 (COMP006) hit primary endpoint in treatment-resistant depression: two 25 mg doses (3 weeks apart) vs 1 mg showed mean MADRS difference of -3.8 at Week 6 (p<0.001). Rapid onset (day after dosing) sustained through Week 6, with durability in COMP005 through Week 26 for responders.
Compass has requested an FDA meeting to discuss rolling submission/review and expects to complete NDA submission in Q4. Classic "new probability of approval" repricing plus short-cover fuel on huge volume.
"Won the trial, lost the day." SOL-1 Phase 3 superiority topline in wet AMD. Primary endpoint at Week 36: 74.1% maintained vision (<15 ETDRS letters lost) vs 55.8% for aflibercept 2 mg, risk difference 17.5% (p=0.0006). Week 52 durability: 65.9% vs 44.2% (p<0.0001), plus higher rescue-free rates. No treatment-related ocular SAEs.
Despite all that, stock got hit. The read: control arm looked "better than feared," so the delta wasn't the knockout some were positioned for. Investors already gaming commercial realism, safety nuance, and "how clean is the FDA story" step.
Regulatory pathway clarity beat uncertainty. FDA declined to grant approval under the national priority voucher fast-track route; Disc will pursue traditional approval path instead. Still guiding late-stage data Q4 2026, potential FDA decision around mid-2027.
Counterintuitive but common: market sometimes prefers a slower, cleaner path over a perceived "accelerated approval" knife fight.
Microcap mechanics plus "milestone" headline. Announced CRO selection for SOTERIA, a Phase 2 open-label, single-arm basket trial of PLX-200 across CLN2, CLN3, Krabbe, and Sandhoff, with initiation planned 1H 2026 (US + ex-US sites).
Operational progress, not efficacy data, so the 60%+ move reads more like float/positioning than fundamentals changing overnight. Still, a real de-risking step for execution timelines.
Publication-driven pop with a specific nuance. Nature Medicine published Phase 2a randomized, placebo-controlled trial of SPL026 (IV DMT) in moderate-to-severe MDD: met primary endpoint with statistically significant, clinically meaningful MADRS improvement at Week 2 (mean diff -7.35; p=0.023), effects seen at Week 1 and sustained in some participants. No treatment-related serious AEs.
Key investor translation: Helus is not advancing IV SPL026 in current form. They're using mechanistic/clinical learnings to guide HLP004 (Phase 2 in GAD), with topline expected Q1 2026.
Classic small-cap biotech financing overhang but also runway. Priced $10.5M registered direct: 1,666,679 shares + pre-funded warrants for up to 1,025,654 shares at $3.90/$3.8999. Proceeds for working capital and advancing bempikibart into future alopecia areata trials.
For a ~$24M market cap name, meaningful raise relative to size. Expect tape to stay "deal-sensitive" until digested.
Small financing, smaller dollars, similar dynamics. Registered direct for 432,902 shares at $2.31 plus concurrent private placement of warrants (Series A-1/A-2). Gross ~$1M (net ~$0.865M), with warrant overhang contingent on stockholder approval. Down mid-single digits.
Capital-structure headline, not a "fundamental up day." Announced 1-for-25 reverse split effective 4:01pm ET Feb 18, post-split trading Feb 19. Aimed at regaining Nasdaq minimum bid compliance. These events often pressure sentiment short-term even though they're mechanically neutral on enterprise value.